

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

NCT07362927

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment	32 participants

Key Eligibility Criteria

Inclusion (7)

- Willing to sign the informed consent, and willing to attend follow-up visits;
- Age ≥ 18;
- Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea;
- CST ≤ 300µm in the study eye at Screening;
- BCVA ETDRS letters between 19 and 73;
- ... and 2 more (see full listing online)

Exclusion (7)

- Active proliferative diabetic retinopathy (PDR);
- Presence of iris neovascularization in the study eye at Screening;
- Retinal laser photocoagulation in the study eye within 3 months prior to Screening;
- Prior gene therapy in the study eye;
- The study eye has been treated with an intravitreal dexamethasone implant (Ozurdex®) within 6 months prior to Screening.
- ... and 2 more (see full listing online)

Locations (2 total)

Shanghai General Hospital, Shanghai, China
Zhongshan Hospital, Shanghai, China